Commodore Capital LP Buys New Stake in Palisade Bio, Inc. $PALI

Commodore Capital LP bought a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,445,000 shares of the company’s stock, valued at approximately $26,896,000. Palisade Bio comprises approximately 1.8% of Commodore Capital LP’s portfolio, making the stock its 22nd largest holding. Commodore Capital LP owned 7.68% of Palisade Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in Palisade Bio during the fourth quarter valued at approximately $16,742,000. Franklin Resources Inc. purchased a new stake in Palisade Bio during the fourth quarter valued at approximately $11,968,000. B Group Inc. purchased a new stake in Palisade Bio during the fourth quarter valued at approximately $10,575,000. Adage Capital Partners GP L.L.C. purchased a new stake in Palisade Bio during the fourth quarter valued at approximately $10,575,000. Finally, Renaissance Technologies LLC purchased a new stake in Palisade Bio during the fourth quarter valued at approximately $5,599,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Analysts Set New Price Targets

PALI has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Wolfe Research initiated coverage on shares of Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target for the company. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright initiated coverage on shares of Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Palisade Bio currently has an average rating of “Moderate Buy” and an average price target of $10.20.

Palisade Bio Price Performance

NASDAQ:PALI opened at $1.76 on Thursday. The firm has a market capitalization of $305.50 million, a P/E ratio of -1.74 and a beta of 1.52. Palisade Bio, Inc. has a 1-year low of $0.53 and a 1-year high of $2.86. The company’s fifty day moving average price is $1.97 and its 200-day moving average price is $1.90.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Equities analysts anticipate that Palisade Bio, Inc. will post -0.21 EPS for the current fiscal year.

Palisade Bio Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.